Targeting FMRP: A new window for cancer immunotherapy

FMRP is regulated by Myc and is highly expressed in a variety of human and mouse tumor tissues. FMRP recruits Treg and M2 macrophages to form an immunosuppressive tumor microenvironment by IL3, PROS1 and exosomes. FMRP‐KO up‐regulates tumor cell secretion of CCL7, which directly activates and recrui...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaguang, Wu, Tong, Han, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030685/
https://www.ncbi.nlm.nih.gov/pubmed/36968189
http://dx.doi.org/10.1002/mco2.233
_version_ 1784910433901084672
author Zhang, Yaguang
Wu, Tong
Han, Junhong
author_facet Zhang, Yaguang
Wu, Tong
Han, Junhong
author_sort Zhang, Yaguang
collection PubMed
description FMRP is regulated by Myc and is highly expressed in a variety of human and mouse tumor tissues. FMRP recruits Treg and M2 macrophages to form an immunosuppressive tumor microenvironment by IL3, PROS1 and exosomes. FMRP‐KO up‐regulates tumor cell secretion of CCL7, which directly activates and recruits CD8+ T cells. FMRP‐KO recruits CCR5 and CXCR4 receptor‐positive CD8 T cells indirectly by promoting M1 macrophages to secrete CCL5, CXCL9, and CXCL10. [Image: see text]
format Online
Article
Text
id pubmed-10030685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100306852023-03-23 Targeting FMRP: A new window for cancer immunotherapy Zhang, Yaguang Wu, Tong Han, Junhong MedComm (2020) Highlights FMRP is regulated by Myc and is highly expressed in a variety of human and mouse tumor tissues. FMRP recruits Treg and M2 macrophages to form an immunosuppressive tumor microenvironment by IL3, PROS1 and exosomes. FMRP‐KO up‐regulates tumor cell secretion of CCL7, which directly activates and recruits CD8+ T cells. FMRP‐KO recruits CCR5 and CXCR4 receptor‐positive CD8 T cells indirectly by promoting M1 macrophages to secrete CCL5, CXCL9, and CXCL10. [Image: see text] John Wiley and Sons Inc. 2023-03-21 /pmc/articles/PMC10030685/ /pubmed/36968189 http://dx.doi.org/10.1002/mco2.233 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Highlights
Zhang, Yaguang
Wu, Tong
Han, Junhong
Targeting FMRP: A new window for cancer immunotherapy
title Targeting FMRP: A new window for cancer immunotherapy
title_full Targeting FMRP: A new window for cancer immunotherapy
title_fullStr Targeting FMRP: A new window for cancer immunotherapy
title_full_unstemmed Targeting FMRP: A new window for cancer immunotherapy
title_short Targeting FMRP: A new window for cancer immunotherapy
title_sort targeting fmrp: a new window for cancer immunotherapy
topic Highlights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030685/
https://www.ncbi.nlm.nih.gov/pubmed/36968189
http://dx.doi.org/10.1002/mco2.233
work_keys_str_mv AT zhangyaguang targetingfmrpanewwindowforcancerimmunotherapy
AT wutong targetingfmrpanewwindowforcancerimmunotherapy
AT hanjunhong targetingfmrpanewwindowforcancerimmunotherapy

Ejemplares similares